EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection

Whitney C Weber iD, Zachary J Streblow, Craig N Kreklywich, Michael Denton, Gauthami Sulgey iD, Magdalene M Streblow, Dorca Marcano iD, Paola N Flores iD, Rachel M Rodriguez-Santiago iD, Luisa I Alvarado, Vanessa Rivera-Amill iD, William B Messer und 5 weitere

Vaccines · 07.08.2024 · 12 (8) · 893

DOI: 10.3390/vaccines12080893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 07.08.2024. Verfasst von Whitney C Weber und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ®, referred to as VLA1553). Other pathogenic alphaviruses co-circulate with CHIKV and major questions remain regarding the potential of IXCHIQ to confer cross-protection for populations that are exposed to them. Here, we characterized the cross-neutralizing antibody (nAb) responses against heterotypic CHIKV and additional arthritogenic alphaviruses in individuals at one month, six months, and one year post-IXCHIQ vaccination. We characterized nAbs against CHIKV strains LR2006, 181/25, and a 2021 isolate from Tocantins, Brazil, as well as O’nyong-nyong virus (ONNV), Mayaro virus (MAYV), and Ross River virus (RRV). IXCHIQ elicited 100% seroconversion to each virus, with the exception of RRV at 83.3% seroconversion of vaccinees, and cross-neutralizing antibody potency decreased with increasing genetic distance from CHIKV. We compared vaccinee responses to cross-nAbs elicited by natural CHIKV infection in individuals living in the endemic setting of Puerto Rico at 8–9 years post-infection. These data suggest that IXCHIQ efficiently and potently elicits cross-nAb breadth that extends to related alphaviruses in a manner similar to natural CHIKV infection, which may have important implications for individuals that are susceptible to alphavirus co-circulation in regions of potential vaccine rollout.

Schlagwörter

Stichwörter der Autor:innen

IXCHIQalphavirusesantibodybreadthchikungunya virus (CHIKV)cross-neutralizationinfectionvaccine

Autor:innen und Institutionen

  • Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
  • Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA.
  • Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.
  • Valneva Austria GmbH, 1030 Vienna, Austria.
  • Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, OR 97006, USA.

ORCID-Profile: Whitney C Weber, Gauthami Sulgey, Dorca Marcano, Paola N Flores, Rachel M Rodriguez-Santiago, Vanessa Rivera-Amill, Karin Kosulin, Vera Buerger, Daniel N Streblow

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • Valneva
  • Valneva sponsored research agreement to OHSU (DNS)
  • National Institutes of Health

Zitieren

APA

Weber, W. C., Streblow, Z. J., Kreklywich, C. N., Denton, M., Sulgey, G., Streblow, M. M., Marcano, D., Flores, P. N., Rodriguez-Santiago, R. M., Alvarado, L. I., Rivera-Amill, V., Messer, W. B., Hochreiter, R., Kosulin, K., Dubischar, K., Buerger, V., & Streblow, D. N. (2024). The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection. Vaccines, 12(8), 893. https://doi.org/10.3390/vaccines12080893

Vancouver

Weber WC, Streblow ZJ, Kreklywich CN, Denton M, Sulgey G, Streblow MM, et al. The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection. Vaccines. 2024;12(8):893. doi:10.3390/vaccines12080893

BibTeX
@article{Weber2024,
  author = {Weber, Whitney C and Streblow, Zachary J and Kreklywich, Craig N and Denton, Michael and Sulgey, Gauthami and Streblow, Magdalene M and Marcano, Dorca and Flores, Paola N and Rodriguez-Santiago, Rachel M and Alvarado, Luisa I and Rivera-Amill, Vanessa and Messer, William B and Hochreiter, Romana and Kosulin, Karin and Dubischar, Katrin and Buerger, Vera and Streblow, Daniel N},
  title = {The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection},
  journal = {Vaccines},
  year = {2024},
  volume = {12},
  number = {8},
  pages = {893},
  doi = {10.3390/vaccines12080893}
}
Kostenlos starten →